(Q24245261)

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

How study design affects outcomes in comparisons of therapy. I: Medical

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Lifetime panic-depression comorbidity in the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

A consumer's guide to subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Affective comorbidity in panic disorder: is there a bipolar connection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Behaviour therapy and benzodiazepines: allies or antagonists?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Suicidal ideation and suicide attempts in panic disorder and attacks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

The cross-national epidemiology of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Cognitive behavioural therapy and pharmacotherapy: complementary or contradictory approaches to the treatment of anxiety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

Long-term outcome of panic disorder with agoraphobia treated by exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

7 January 2021

Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

7 January 2021

A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

7 January 2021

Panic disorder: long-term pharmacotherapy and discontinuation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

7 January 2021

Duration of imipramine therapy and relapse in panic disorder with agoraphobia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335

7 January 2021